Literature DB >> 16132896

Pretreatment with peroxysome proliferator-activated receptor alpha agonist fenofibrate protects endothelium in rabbit Escherichia coli endotoxin-induced shock.

Eric Wiel1, Gilles Lebuffe, Emmanuel Robin, Gaëlle Gasan, Delphine Corseaux, Benoît Tavernier, Brigitte Jude, Régis Bordet, Benoît Vallet.   

Abstract

OBJECTIVE: To investigate the effects of fenofibrate, an activator of peroxysome proliferator activated receptor (PPAR) alpha, on vascular endothelium and on hemostasis in a rabbit endotoxic shock model. DESIGN AND
SETTING: Prospective laboratory study in a university laboratory.
SUBJECTS: 36 male New Zealand rabbits weighing 2.5-3 kg.
INTERVENTIONS: We determined in vitro vascular reactivity, endothelium CD31-platelet/endothelial cell adhesion molecule (PECAM) 1 immunohistochemistry, plasma coagulation factors, and monocyte tissue factor expression 5 days after onset of endotoxic shock (0.5 mg/kg intravenous bolus, Escherichia coli lipopolysaccharide) with or without treatment by fenofibrate (mixed in the chow at a concentration of 0.5%) for 15 days before lipopolysaccharide injection and 5 days afterward. MEASUREMENTS AND
RESULTS: Metabolic acidosis and coagulation activation confirmed presence of shock. Fenofibrate decreased monocyte tissue factor expression. It improved endothelial-dependent relaxation at 5 days (Emax=68.2+/-3.3%, vs. 44.2+/-2.5% in the non-treated group). Endotoxin-induced deendothelialization was significantly decreased by fenofibrate at 5 days (8.5+/-1.3% vs. 19.2+/-3.1% in the nontreated group) .
CONCLUSIONS: These data indicate for the first time that fenofibrate, an activator of PPAR-alpha, inhibits monocyte tissue factor expression and protects against endothelial dysfunction and histological injury in endotoxin-induced shock.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16132896     DOI: 10.1007/s00134-005-2730-1

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  55 in total

Review 1.  Shock- and ischemia-induced mechanisms of impairment of endothelium-mediated vasodilation.

Authors:  A M Lefer; P S Tsao; X L Ma
Journal:  Chest       Date:  1991-09       Impact factor: 9.410

2.  PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells.

Authors:  Yves Rival; Nathalie Benéteau; Thierry Taillandier; Mylène Pezet; Elisabeth Dupont-Passelaigue; Jean François Patoiseau; Didier Junquéro; Francis C Colpaert; André Delhon
Journal:  Eur J Pharmacol       Date:  2002-01-25       Impact factor: 4.432

3.  Anti-EDRF effect of tumor necrosis factor in isolated, perfused cat carotid arteries.

Authors:  N Aoki; M Siegfried; A M Lefer
Journal:  Am J Physiol       Date:  1989-05

4.  Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1.

Authors:  P Delerive; K De Bosscher; S Besnard; W Vanden Berghe; J M Peters; F J Gonzalez; J C Fruchart; A Tedgui; G Haegeman; B Staels
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

5.  Effect of L-arginine on endothelial injury and hemostasis in rabbit endotoxin shock.

Authors:  E Wiel; Q Pu; D Corseaux; E Robin; R Bordet; N Lund; B Jude; B Vallet
Journal:  J Appl Physiol (1985)       Date:  2000-11

6.  Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice.

Authors:  D P Mikhailidis; E S Ganotakis; K A Spyropoulos; I A Jagroop; D J Byrne; A F Winder
Journal:  Int Angiol       Date:  1998-12       Impact factor: 2.789

7.  Enhanced monocyte tissue factor response after experimental balloon angioplasty in hypercholesterolemic rabbit: inhibition with dietary L-arginine.

Authors:  D Corseaux; T Le Tourneau; I Six; M D Ezekowitz; E P Mc Fadden; T Meurice; P Asseman; C Bauters; B Jude
Journal:  Circulation       Date:  1998-10-27       Impact factor: 29.690

8.  Hydrogen peroxide metabolism during peroxisome proliferation by fenofibrate.

Authors:  S L Arnaiz; M Travacio; S Llesuy; A Boveris
Journal:  Biochim Biophys Acta       Date:  1995-12-12

9.  Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response.

Authors:  N Hennuyer; P Poulain; L Madsen; R K Berge; L M Houdebine; D Branellec; J C Fruchart; C Fiévet; N Duverger; B Staels
Journal:  Circulation       Date:  1999-05-11       Impact factor: 29.690

10.  Endothelial-dependent and -independent responses in the thoracic aorta during endotoxic shock.

Authors:  J S Young; J P Headrick; R M Berne
Journal:  Circ Shock       Date:  1991-09
View more
  11 in total

Review 1.  Involvement of PPAR nuclear receptors in tissue injury and wound repair.

Authors:  Liliane Michalik; Walter Wahli
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

Review 2.  Year in review in intensive care medicine, 2005. III. Nutrition, pediatric and neonatal critical care, and experimental.

Authors:  Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker
Journal:  Intensive Care Med       Date:  2006-02-18       Impact factor: 17.440

Review 3.  Early Diagnosis of Sepsis: Is an Integrated Omics Approach the Way Forward?

Authors:  Raymond J Langley; Hector R Wong
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

Review 4.  Sepsis and Septic Shock: Current Treatment Strategies and New Approaches.

Authors:  Gizem Polat; Rustem Anil Ugan; Elif Cadirci; Zekai Halici
Journal:  Eurasian J Med       Date:  2017-02

5.  Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis.

Authors:  Go Haraguchi; Hisanori Kosuge; Yasuhiro Maejima; Jun-Ichi Suzuki; Takasuke Imai; Masayuki Yoshida; Mitsuaki Isobe
Journal:  Intensive Care Med       Date:  2008-02-19       Impact factor: 17.440

6.  Integrative "omic" analysis of experimental bacteremia identifies a metabolic signature that distinguishes human sepsis from systemic inflammatory response syndromes.

Authors:  Raymond J Langley; Jennifer L Tipper; Shannon Bruse; Rebecca M Baron; Ephraim L Tsalik; James Huntley; Angela J Rogers; Richard J Jaramillo; Denise O'Donnell; William M Mega; Mignon Keaton; Elizabeth Kensicki; Lee Gazourian; Laura E Fredenburgh; Anthony F Massaro; Ronny M Otero; Vance G Fowler; Emanuel P Rivers; Chris W Woods; Stephen F Kingsmore; Mohan L Sopori; Mark A Perrella; Augustine M K Choi; Kevin S Harrod
Journal:  Am J Respir Crit Care Med       Date:  2014-08-15       Impact factor: 21.405

7.  New insights into the role of peroxisome proliferator-activated receptors in regulating the inflammatory response after tissue injury.

Authors:  Miriam D Neher; Sebastian Weckbach; Markus S Huber-Lang; Philip F Stahel
Journal:  PPAR Res       Date:  2012-02-29       Impact factor: 4.964

8.  Gemfibrozil attenuates the inflammatory response and protects rats from abdominal sepsis.

Authors:  Carlos R Cámara-Lemarroy; Francisco J Guzman-DE LA Garza; Paula Cordero-Perez; Juan M Ibarra-Hernandez; Linda E Muñoz-Espinosa; Nancy E Fernandez-Garza
Journal:  Exp Ther Med       Date:  2015-01-19       Impact factor: 2.447

9.  Activated protein C increases sensitivity to vasoconstriction in rabbit Escherichia coli endotoxin-induced shock.

Authors:  Eric Wiel; Marion Elizabeth Costecalde; Gilles Lebuffe; Delphine Corseaux; Brigitte Jude; Régis Bordet; Benoît Tavernier; Benoît Vallet
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

10.  Statins, fibrates, thiazolidinediones and resveratrol as adjunctive therapies in sepsis: could mitochondria be a common target?

Authors:  Jerome Morel; Mervyn Singer
Journal:  Intensive Care Med Exp       Date:  2014-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.